PNPLA3 and metabolic dysfunction-associated steatotic liver disease: To validate the use of FatTracer for CRISPR-LOF screening, we included some effective targets identified in our drug screening (that is, DGAT2, ACC (ACACA/B) and FAS (FASN)), as well as PNPLA3 as a proxy to interrogate NAFLD risk genes.